Malaria remains the most common serious illness of children in Africa. There is increasing interest in the use of chemopreventive strategies for infants and young children, generally intermittent preventive therapy (IPT) with sulfadoxine-pyrimethamine (SP). However, the optimal drugs or dosing strategies for IPT have not been identified. Concurrently, standard policy for HIV-infected children now includes chemoprophylaxis with trimethoprim-sulfamethoxazole (TS), which offers a high degree of protection against malaria. Given increasing levels of resistance to the antifolate drugs (TS and SP), newer drugs, such as the arteminsininbased combination therapy dihydroartemisinin-piperaquine (DP), may offer better preventive efficacy. Considering this background, it is an urgent priority to identify optimal chemopreventive strategies for malaria in African children, as well as assess potential drawbacks of different regimens, such as increased toxicity or an increased risk of malaria after discontinuation of chemoprevention (rebound). We will compare the efficacy and safety of three chemopreventive strategies with no chemoprevention, which is the current standard of care, among infants and children in Uganda.
The specific aims will be: 1) to compare the incidence of malaria among infants and children enrolled at 4-12 months of age and randomized to receive no chemoprevention, daily TS, monthly SP, or monthly DP;2) to compare the incidence of adverse events among infants and children enrolled at 4-12 months of age and randomized to receive no chemoprevention, daily TS, monthly SP, or monthly DP;and 3) to compare the incidence of malaria among children for 1 year following intervention with no chemoprevention, daily TS, monthly SP, or monthly DP. This study will be a randomized, open-label, trial of 800 HIV-uninfected infants randomized to equal numbers of each intervention arm. Participants will be followed for all routine and acute medical care until they reach the age of 36 months. Chemoprevention will be stopped at 24 months of age to allow for 1 additional year of followup post-intervention. The primary study endpoint will be the incidence of symptomatic malaria. Secondary endpoints will include incidence of complicated malaria, diarrheal illnesses and respiratory tract infections; prevalence of asymptomatic parasitemia, anemia, and gametocytemia;and incidence of adverse events to study drugs.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-AARR-C)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Wallender, Erika; Vucicevic, Katarina; Jagannathan, Prasanna et al. (2018) Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis 217:964-972
Odorizzi, Pamela M; Jagannathan, Prasanna; McIntyre, Tara I et al. (2018) In utero priming of highly functional effector T cell responses to human malaria. Sci Transl Med 10:
Savic, Rada M; Jagannathan, Prasanna; Kajubi, Richard et al. (2018) Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis 67:1079-1088
Jagannathan, Prasanna; Kakuru, Abel; Okiring, Jaffer et al. (2018) Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med 15:e1002606
Jagannathan, Prasanna; Kajubi, Richard; Aweeka, Francesca T (2018) Response to ""Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction"". Clin Pharmacol Ther 103:571
Conroy, Andrea L; McDonald, Chloe R; Gamble, Joel L et al. (2017) Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV. Am J Obstet Gynecol 217:684.e1-684.e17
Kapisi, James; Kakuru, Abel; Jagannathan, Prasanna et al. (2017) Relationships between infection with Plasmodium falciparum during pregnancy, measures of placental malaria, and adverse birth outcomes. Malar J 16:400
Prahl, Mary; Jagannathan, Prasanna; McIntyre, Tara I et al. (2017) Sex Disparity in Cord Blood FoxP3+ CD4 T Regulatory Cells in Infants Exposed to Malaria In Utero. Open Forum Infect Dis 4:ofx022
Sonoiki, Ebere; Nsanzabana, Christian; Legac, Jennifer et al. (2017) Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1. Antimicrob Agents Chemother 61:
Kajubi, R; Huang, L; Jagannathan, P et al. (2017) Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther 102:520-528

Showing the most recent 10 out of 59 publications